Journey Medical Corp (DERM) — SEC Financial Statements & Analysis

Journey Medical Corp (DERM) is a pharmaceutical preparations company, incorporated in DE. Journey Medical Corp trades on Nasdaq as: DERM. Journey Medical Corp (DERM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Journey Medical Corp carries a market cap of $194.66M, a P/E ratio of -31.89x, a P/B ratio of 6.06x, a P/S ratio of 2.91x, an enterprise value of $194.48M, and an EV/EBITDA multiple of 159.94x. On profitability, it posts a gross margin of 69.86%, an operating margin of -4.50%, a net margin of -9.13%, a Return on Equity (ROE) of -23.77%, a Return on Assets (ROA) of -6.80%, and a Return on Invested Capital (ROIC) of -10.29%. Per share, it reports EPS of $-0.22, diluted EPS of $-0.22, free cash flow per share of $-0.27, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 18.54% year-over-year, net income growth of -30.14% year-over-year, and EPS growth of -40.82% year-over-year. On the balance sheet, it maintains a current ratio of 1.59x, a quick ratio of 1.35x, working capital of $27.01M, a debt-to-equity ratio of 2.06x, a debt ratio of 0.67, an interest coverage ratio of -0.82x, free cash flow of $-7.49M (TTM), and net debt of $-171.00K. Figures sourced from SEC EDGAR.

Market Cap

$194.66M

P/E TTM

-31.89x

EPS TTM

$-0.22

P/B TTM

6.06x

ROE TTM

-23.77%

ROA TTM

-6.80%

Debt To Equity

2.06x

Free Cash Flow TTM

$-7.49M

Net Revenue TTM Growth 1Y

18.54%

Data as of 2026-06-30 · Source: SEC EDGAR